Commentary
Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents
Johanna N. Spaans, Timothy R. Asmis, Gonzalo G. Alvarez and Glenwood D. Goss
CMAJ April 15, 2014 186 (7) 485-486; DOI: https://doi.org/10.1503/cmaj.131011
Johanna N. Spaans
Ottawa Hospital Research Institute (Spaans, Alvarez, Goss); Ottawa Hospital Cancer Centre (Asmis, Goss); Department of Medicine (Asmis, Alvarez, Goss), University of Ottawa, Ottawa, Ont.
MScTimothy R. Asmis
Ottawa Hospital Research Institute (Spaans, Alvarez, Goss); Ottawa Hospital Cancer Centre (Asmis, Goss); Department of Medicine (Asmis, Alvarez, Goss), University of Ottawa, Ottawa, Ont.
MDGonzalo G. Alvarez
Ottawa Hospital Research Institute (Spaans, Alvarez, Goss); Ottawa Hospital Cancer Centre (Asmis, Goss); Department of Medicine (Asmis, Alvarez, Goss), University of Ottawa, Ottawa, Ont.
MDGlenwood D. Goss
Ottawa Hospital Research Institute (Spaans, Alvarez, Goss); Ottawa Hospital Cancer Centre (Asmis, Goss); Department of Medicine (Asmis, Alvarez, Goss), University of Ottawa, Ottawa, Ont.
MDIn this issue
Article tools
Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents
Johanna N. Spaans, Timothy R. Asmis, Gonzalo G. Alvarez, Glenwood D. Goss
CMAJ Apr 2014, 186 (7) 485-486; DOI: 10.1503/cmaj.131011
Related Articles
Cited By...
- No citing articles found.